Volume 23, Issue 3 e13371
CASE REPORT

De novo leukocyte chemotactic factor 2 amyloidosis in a pediatric renal allograft, 15 years post-transplant

Eliah R. Shamir

Eliah R. Shamir

Department of Pathology, University of California San Francisco, San Francisco, California

Search for more papers by this author
Marsha M. Lee

Marsha M. Lee

Department of Pediatric Nephrology, University of California San Francisco, San Francisco, California

Search for more papers by this author
Vighnesh Walavalkar

Corresponding Author

Vighnesh Walavalkar

Department of Pathology, University of California San Francisco, San Francisco, California

Correspondence

Vighnesh Walavalkar, Department of Pathology, UCSF Medical Center, San Francisco, CA.

Email: [email protected]

Search for more papers by this author
First published: 03 February 2019
Citations: 4

Abstract

Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a recently described form of systemic amyloidosis, which most commonly affects the kidney and liver. The LECT2 protein is produced during inflammatory processes, but its precise function in renal diseases in unclear. ALECT2, however, is known to be a relatively common form of renal amyloidosis, after amyloid light chain and serum amyloid A types and is most often seen in patients of Hispanic ethnicity. ALECT2 can occur de novo or as recurrent disease in kidney transplants. We present the first case, to our knowledge, of de novo ALECT2 in a pediatric kidney transplant patient, 15 years post-transplant.

CONFLICT OF INTEREST

The authors of this article have no conflict of interests to disclose as described by Pediatric Transplantation.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.